A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With Relapsed/Refractory Small Cell Lung Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 25 Nov 2019
Price : $35 *
At a glance
- Drugs AMG-119 (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; First in man
- Sponsors Amgen
- 21 Nov 2019 Planned End Date changed from 30 Jun 2021 to 10 Mar 2020.
- 21 Nov 2019 Planned primary completion date changed from 30 Jun 2021 to 10 Mar 2020.
- 10 Jul 2019 Status changed from recruiting to active, no longer recruiting.